TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04613596
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib 400 mg twice daily (BID) in combination with pembrolizumab (Cohort 1a)
Study: NCT04613596
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib 600 mg BID monotherapy (Cohort 1b)
Study: NCT04613596
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adagrasib 400 mg BID in combination with pembrolizumab
Study: NCT04613596
Drug: Adagrasib
Normalized name: Adagrasib
DrugBank: Adagrasib (DB15568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adagrasib 400 mg BID + pembrolizumab 200 mg every Q3W
Study: NCT04613596
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200 mg IV Q3W
Study: NCT02312622
Drug: Pegylated Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
Study: NCT01437813
Drug: Glimepiride/ Extended release Metformin
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
Study: NCT04420741
Drug: Iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuously infusion for 72 hours at 3 ml/hours. Treatment dose 1 ng/kg/min
Study: NCT02609776
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
Study: NCT02609776
Drug: Amivantamab
Normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
Study: NCT02609776
Drug: Lazertinib
Normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
Study: NCT02609776
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
Study: NCT02609776
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
Study: NCT02671578
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
Study: NCT04253964
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ALL PARTICIPANTS: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle for 4 cycles. Participants with predictive biomarker PD-L1 greater than or equal to 50% will not receive any other drugs besides pembrolizumab.
Study: NCT01529541
Drug: Anagliptin
Normalized name: Anagliptin
DrugBank: Anagliptin (DB12417)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Anagliptin 100mg, tablet, twice a day (BID)
Study: NCT01529541
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg, tablet, once a day (QD)
Study: NCT00647998
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
Study: NCT04253964
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: FOR PARTICIPANTS IN EITHER ARM with non-squamous OR squamous subtype, predictive biomarker PD-L1 less than 50%: Carboplatin area under the curve (AUC) 5 IV on day 1 of each 3-week cycle for 4 cycles.
Study: NCT04253964
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Paclitaxel 200 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
Study: NCT04253964
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FOR PARTICIPANTS IN EITHER ARM with squamous subtype, predictive biomarker PD-L1 less than 50%: Nab-paclitaxel 100 mg/m2 on day 1, 8, 15 of 3-week cycle for 4 cycles.
Study: NCT01333137
Drug: Gemcitabine and Carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
Study: NCT01333137
Drug: P276-00 along with Gemcitabine and carboplatin
Normalized name: Carboplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
Study: NCT00131183
Drug: Nebido
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00104975
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00104975
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00104975
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00104975
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02639078
Drug: TD-0714
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One time dosing in capsule formulation
Study: NCT00169585
Drug: Levofloxacin oral tablets
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02723383
Drug: BACLOFEN
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
Study: NCT00005797
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
Study: NCT00005797
Drug: VP-16
Normalized name: Provp-16i
DrugBank: Etoposide toniribate (DB17255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is \>/= 150% of IBW, in which case adjusted body weight will be used.
Study: NCT03891498
Drug: MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The magnesium sulfate will be given according to the regimen of 6 grams intravenous over 20 minutes as a loading dose.
Study: NCT04253964
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FOR PARTICIPANTS IN EITHER ARM with nonsquamous subtype, predictive biomarker PD-L1 less than 50%: Pemetrexed 500 mg/m2 IV on day 1 of each 3-week cycle for 4 cycles.
Study: NCT00543101
Drug: Darunavir (DRV/r)
Normalized name: Darunavir
DrugBank: Darunavir (DB01264)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Switch to DRV/r at a dose of 600/100 BID for 48 weeks
Study: NCT00543101
Drug: continue on current dual boosted PI
Normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (\< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
Study: NCT01364441
Drug: ONO-2952
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
Study: NCT00694564
Drug: S-adenosyl methionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
Study: NCT00004403
Drug: albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004403
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01346930
Drug: Macitentan
Normalized name: Macitentan
DrugBank: Macitentan (DB08932)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 10 mg, tablet, once daily
Study: NCT03494907
Drug: Seltorexant
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered oral dose of seltorexant over-encapsulated tablets on Day 1.
Study: NCT04157959
Drug: Febuxostat dose2
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet,dose2,QD
Study: NCT03494907
Drug: Moxifloxacin Dose 1
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered oral dose 1 of moxifloxacin on Day 1.
Study: NCT03036150
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg or 5 mg tablets given once daily, per oral use.
Study: NCT00392886
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00392886
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00392886
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and orally
Study: NCT00392886
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT00392886
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00392886
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01193062
Drug: PF-04995274
Normalized name: PF-04995274
DrugBank: PF-04995274 (DB12675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
Study: NCT03547037
Drug: JNJ-63723283
Normalized name: JNJ-63723283
DrugBank: Cetrelimab (DB15421)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-63723283 will be administered intravenously.
Study: NCT03547037
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erdafitinib will be administered orally.
Study: NCT01193062
Drug: PF-04995274
Normalized name: PF-04995274
DrugBank: PF-04995274 (DB12675)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
Study: NCT03841617
Drug: Thyrogen
Normalized name: Thyrogen
DrugBank: Thyrotropin alfa (DB00024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intramuscular injection administered once/day for 2 consecutive days at Week 3; then once annually for subjects who meet criteria.
Study: NCT06123364
Drug: mirabegron 50 mg daily
Normalized name: mirabegron 50 MG
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in both study groups will receive 50 mg of mirabegron daily in the form of tablets, which is used to treat OAB according to current treatment guidelines.
Study: NCT03317392
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01484314
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
Study: NCT03617016
Drug: Domperidone
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive domperidone tablets orally.
Study: NCT02606084
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
Study: NCT03649997
Drug: JNJ-61393215
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
Study: NCT03649997
Drug: JNJ-61393215
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Study: NCT03630692
Drug: observance of oral drug treatment
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Completion of questionnaires at 4 times during patient's oral route drug treatment
Study: NCT02090998
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
Study: NCT02209727
Drug: 131I-Sibrotuzumab
Normalized name: iobenguane (131I)
DrugBank: Sibrotuzumab (DB06474)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg Sibrotuzumab conjugated with 131I
Study: NCT04531813
Drug: Butenafine HCl 1% (BAY1896425)
DrugBank: Butenafine (DB01091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
Study: NCT04531813
Drug: Positive Control-Sodium lauryl sulfate (SLS)
Normalized name: Sodium Lauryl Sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.
Study: NCT04613622
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
Study: NCT02853305
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02853305
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT02853305
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT01685125
Drug: abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01685125
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01685125
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00018044
Drug: Clofazimine
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01575548
Drug: Pazopanib Hydrochloride
Normalized name: Pazopanib Hydrochloride
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01585688
Drug: hLL1-DOX (IMMU-115)
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
Study: NCT02370199
Drug: octafluropropane
Normalized name: pentafluoropropane
DrugBank: Pentafluoropropane (DB13117)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
Study: NCT04513912
Drug: Seltorexant
Normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive seltorexant over-encapsulated tablet orally.
Study: NCT04513912
Drug: Matching placebo to Seltorexant
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.
Study: NCT04513912
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive quetiapine XR capsule orally.
Study: NCT04513912
Drug: Matching placebo to Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive placebo capsule matching to quetiapine XR orally.
Study: NCT04175600
Drug: Selexipag
Normalized name: Selexipag
DrugBank: Selexipag (DB11362)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selexipag tablet will be administered orally.
Study: NCT02076009
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; and every 4 weeks for cycles 7 and onwards. Following amendment 8, participants receiving daratumumab IV have the option to switch to daratumumab subcutaneous (SC) 1800 mg/dose until documented progression, unacceptable toxicity, or the end of study on Day 1 of any cycle, at the discretion of the investigator.
Study: NCT02076009
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
Study: NCT02076009
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants \> 75 years old or with a body mass index \< 18.5).
Study: NCT04033445
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive guselkumab IV or SC.
Study: NCT00640523
Drug: forodesine HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Forodesine (DB06185)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 2 x 100mg capsules daily
Study: NCT03942120
Drug: Ustekinumab
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants treated with ustekinumab under real world clinical practice will be observed in this study. No study drug will be administered as a part of this study.
Study: NCT03375697
Drug: JNJ-63733657
Normalized name: Immunoglobulin G1, anti-(human phosphorylated tau protein) (human-Mus musculus monoclonal JNJ-63733657 γ1-chain), disulfide with human-Mus musculus monoclonal JNJ-63733657 κ-chain, dimer
DrugBank: Posdinemab (DB18941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single (Part 1) or multiple (Part 2) ascending dose levels of JNJ-63733657 intravenously.